Bosutinib Pathway, Pharmacokinetics/Pharmacodynamics

Overview
Components
Related Pathways
Associations
Related Literature
Downloads
Navigate to...
Show section selector dropdown

Literature

The publications shown below are associated with this pathway in PharmGKB based on (1) literature annotations, (2) variant annotations, (3) VIP summaries, or (4) pathways.

    8 items
    Literature
    Pharmacogenetics of BCR/ABL Inhibitors in Chronic Myeloid Leukemia.
    International journal of molecular sciences. 2015. Polillo Marialuisa, Galimberti Sara, Baratè Claudia, Petrini Mario, Danesi Romano and Di Paolo Antonello.
    Literature
    Bosutinib for the treatment of chronic myeloid leukemia.
    American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists. 2015. Doan Vi, Wang Alice and Prescott Hillary.
    Literature
    ABCB1 haplotypes do not influence transport or efficacy of tyrosine kinase inhibitors in vitro.
    Pharmacogenomics and personalized medicine. 2013. Skoglund Karin, Moreno Samuel Boiso, Baytar Maria, Jönsson Jan-Ingvar and Gréen Henrik.
    Literature
    Bosutinib in the management of chronic myelogenous leukemia.
    Biologics : targets & therapy. 2013. Amsberg Gunhild Keller-von and Schafhausen Philippe.
    Literature
    Effect of ketoconazole on the pharmacokinetics of oral bosutinib in healthy subjects.
    Journal of clinical pharmacology. 2011. Abbas Richat, Hug Bruce A, Leister Cathie, Burns Jaime and Sonnichsen Daryl.
    Literature
    Interaction of nilotinib, dasatinib and bosutinib with ABCB1 and ABCG2: implications for altered anti-cancer effects and pharmacological properties.
    British journal of pharmacology. 2009. Hegedus C, Ozvegy-Laczka C, Apáti A, Magócsi M, Német K, Orfi L, Kéri G, Katona M, Takáts Z, Váradi A, Szakács G and Sarkadi B.
    Literature
    Global target profile of the kinase inhibitor bosutinib in primary chronic myeloid leukemia cells.
    Leukemia. 2009. Remsing Rix L L, Rix U, Colinge J, Hantschel O, Bennett K L, Stranzl T, Müller A, Baumgartner C, Valent P, Augustin M, Till J H and Superti-Furga G.
    Literature
    In vitro and in vivo activity of SKI-606, a novel Src-Abl inhibitor, against imatinib-resistant Bcr-Abl+ neoplastic cells.
    Cancer research. 2006. Puttini Miriam, Coluccia Addolorata Maria Luce, Boschelli Frank, Cleris Loredana, Marchesi Edoardo, Donella-Deana Arianna, Ahmed Shaheen, Redaelli Sara, Piazza Rocco, Magistroni Vera, Andreoni Federica, Scapozza Leonardo, Formelli Franca and Gambacorti-Passerini Carlo.